Development Partner International and Amethis invest in Marcyrl Pharmaceutical Industries to enhance access to essential medications in Africa.

Information on the Target

Marcyrl Pharmaceutical Industries, established in 1998, is a leading Egyptian manufacturer specializing in essential pharmaceutical products, primarily focusing on generic medications. The company's mission is to enhance access to specialized generic drugs in Egypt and across Africa. Over the years, Marcyrl has demonstrated significant growth, achieving stable sales and capturing over 2% of the market share in Egypt last year. The company’s recent efforts involve innovating its product portfolio and entering new therapeutic areas, such as hormone therapy, which was added in 2016. Moreover, Marcyrl pioneered the production and launch of antiviral products in 2015, notably effective treatments for hepatitis C.

Industry Overview in Egypt

The African pharmaceutical market is vast, with an annual demand for packaged drugs valued at $18 billion. However, more than 60% of these products are still imported, which limits accessibility and increases costs for communities across the continent. The market for specialty generics is experiencing rapid growth, driven by the rising prevalence of chronic diseases. This presents a significant opportunity for manufacturers like Marcyrl, positioned at the forefront of pharmaceutical innovation.

In Egypt, the pharmaceutical industry is marked by a mix of local and international players. The market is characterized by an increasing demand for generic and specialty medications due to healt